Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies.
Recent great advances in the neuropharmacology of the emetic pathways have led to better therapy and improved insight into pathophysiological processes in patients undergoing chemo- and radiotherapy. This article gives an overview of the area, outlines current controversies and makes recommendations for future clinical studies.
Andrews
P L
PL
Department of Physiology, St. George's Hospital Medical School, Tooting, London, UK.
Naylor
R J
RJ
Joss
R A
RA
D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D004064:Digestive System / Q000294:innervation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D010166:Palliative Care; D018040:Receptors, Neurokinin-1 / Q000187:drug effects* / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
D000932:Antiemetics; D018040:Receptors, Neurokinin-1; D011985:Receptors, Serotonin